Loading clinical trials...

Cetuxibab to Reduce Circulating Tumor Cells in Early Stage NSCLC | Clinical Trials | Clareo Health

WITHDRAWNPHASE2

Cetuxibab to Reduce Circulating Tumor Cells in Early Stage NSCLC

Are Anti-EGFR Monoclonal Antibodies the Magic Bullets That Remove Circulating EGFR+EpCAM+ Tumor Cells in Patients With Non-small Cell Lung Cancer

NCT04648189•The Netherlands Cancer Institute

View on ClinicalTrials.gov

Summary

Cetuximab to reduce the amound of circulating tumor cells in early stage NSCLC

Detailed Description

A multicenter single arm phase II trial. 40 patients with pathology proven stage I-IIIA NSCLC that are eligible for resection will be enrolled in this study. All patients will receive one dose of cetuximab prior to surgery. Blood will be drawn on multiple timepoints to assess te amount of circulating tumor cells

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•18 years or older
•Presence of surgically resectable NSCLC, stage I-IIIA, with curative intent surgery planned.
•≥10 EGFR+EpCAM+ cells detected in the baseline blood sample.
•Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of treatment. Both men and women enrolled in this trial must agree to use adequate barrier birth control measures (e.g., cervical cap, condom, and diaphragm) during the course of the trial. Oral birth control methods alone will not be considered adequate on this study, because of the potential pharmacokinetic interaction between study drug and oral contraceptives. Concomitant use of oral and barrier contraceptives is advised. Contraception is necessary for at least 6 months after receiving study drug

Exclusion Criteria

•Chemotherapy or other anti-cancer therapy including radiotherapy during the study or within 4 weeks prior to the start of the study.
•Prior anti-EGFR mAb therapy
•Other currently active malignancy
•Immunosuppressive drugs during the study or within 4 weeks prior to the start of te study
•Expected adverse reactions/allergies or study medication
•Mental disorder/unable to give informed consent
•Pregnancy or breast-feeding patients
•Significant skin condition interfering with treatment
•Major surgery within 28 days before start of study.
•Substance abuse, medical, psychological or social conditions that may interfere with the subject's participation in the study or evaluation of the study results.
+1 more criteria

Locations (2)

Amsterdam UMC - VUMC

Amsterdam, Netherlands

Leiden University Medical Center

Leiden, Netherlands

Key Dates

Start Date

January 1, 2022

Primary Completion Date

September 19, 2022

Completion Date

September 19, 2022

Last Updated

October 19, 2023

Conditions

Lung CancerSurgeryCirculating Tumor Cell

Interventions

Cetuximab

DRUG

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

NCT07485114

Renal Cell Carcinoma (Kidney Cancer)Non Small Cell Lung Cancer+2 more

View study

RECRUITING

Magnetic Resonance Imaging of the Lung: Oncological Applications

NCT07486219

Lung Cancer (NSCLC)

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 19, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Cetuxibab to Reduce Circulating Tumor Cells in Early Stage NSCLC

Inclusion Criteria

Exclusion Criteria

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

Magnetic Resonance Imaging of the Lung: Oncological Applications

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance